Intravenous Insulin in Patients With Diabetes After Percutaneous Coronary Intervention (PCI)

H

Hospital de Clinicas de Porto Alegre

Status

Terminated

Conditions

Percutaneous Coronary Intervention
Diabetes Mellitus

Treatments

Drug: Intravenous Insulin

Study type

Interventional

Funder types

Other

Identifiers

NCT00967642
06036

Details and patient eligibility

About

The purpose of this study is to evaluate the effects of intravenous insulin/24 hours to normalize glycemia upon markers of oxidative stress (protein oxidation and total antioxidant defense) and inflammation (C-reactive protein (CRP) and sCD40L) in diabetic patients submitted to PCI with stent.

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with Diabetes Mellitus submitted to Percutaneous Coronary Intervention with Stent bare metal
  • Age: 18-80 years old

Exclusion criteria

  • Restenosis
  • Drug elution stent
  • Acute coronary syndrome at last 30 days
  • Use anti inflammatory, antibiotic, vitamin E
  • Inflammatory disease or oncologic

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

70 participants in 2 patient groups

standard treatment
No Intervention group
Description:
glycemia before meals and subcutaneous regular insulin if higher than 200 mg/dl
Intravenous Insulin
Other group
Description:
intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
Treatment:
Drug: Intravenous Insulin

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems